Daily Mail

STOCK WATCH

-

DRUGS company Clinigen is on track to toast another year of growth after a surge in first-half sales.

The pharmaceut­ical firm, which supplies unlicensed drugs to patients in critical need, saw a 28pc rise in the six months to December 31. Profits rose 10pc.

The boost was due to the strong performanc­e of its commercial business and the two-month inclusion of Quantum Pharma, which it acquired in September. Shares fell 3pc, or 31p, to 1003p.

 ??  ??

Newspapers in English

Newspapers from United Kingdom